News & Events

Australia Chase Sun Pty Ltd

Chase Sun Wins 2024 Excellence in Pharmaceutical Quality Award

2024-09-24
ChoiceMMed Showcases Innovative Medical Technologies at Medical Fair Asia 2024

2024-09-18
Chase Sun Pharma Named Among "Top 100 Chinese Pharmaceutical Companies"

2024-09-09
Chairman Wu Wenyuan Visits Hubei Yinuorui Biopharmaceutical

2024-08-12
Chase Sun Pharma Named in "Top 100 Comprehensive Strength in Drug R&D i

On July 4th, the 2024 International Pharmaceutical Service Industry Innovation Development Conference and the 9th China Pharmaceutical R&D and Innovation Summit (PDI) kicked off at the Xiongan Exhibition Center. During the event, Chase Sun Pharma was honored on the "Top 100 Comprehensive Strength in Drug R&D in China 2024" list, acknowledging its robust R&D capabilities and innovative advancements.

2024-07-05
Chengdu Xingcheng Group Visits Chase Sun Pharma for Guidance and Inspection

Mr Chen Dayong, Deputy Secretary of the Party Committee, Vice Chairman, and General Manager of Chengdu Xingcheng Group, along with Zeng Qiang, Deputy General Manager, Chief Compliance Officer, and Chief Legal Counsel, visited Chase Sun Pharma.

2024-07-04
Chase Sun Achieves Top Ranking in Chinese Herbal Medicine Industry

Chase Sun Pharmaceuticals has secured a place in the "Top 100 Chinese Pharmaceutical Companies" rankings by Menet, a leading Chinese health information platform. This accolade highlights Chase Sun's strong innovation and promotional capabilities. Recognized for its robust R&D, the company excels in areas such as TCM formula granules, finished drugs, and medical devices.

2024-06-26
ChoiceMMed Showcases Innovative Health Technology at ATA 2024

From May 5th to 7th, ChoiceMMed, a subsidiary of Hongri Pharmaceuticals, exhibited its latest health technology products at the ATA 2024 conference in Phoenix, Arizona. Their innovative solutions, including a compact multi-parameter detector, garnered significant attention for their advanced features and connectivity to health cloud services.

2024-06-22
Xuebijing Injection Study Highlighted at ATS 2024, Showcasing TCM's Potential in

At the American Thoracic Society (ATS) annual meeting in San Diego, a significant study on Xuebijing Injection, developed by Chase Sun Pharma, was highlighted for its efficacy in treating sepsis. The study, published in JAMA Internal Medicine, underscores the growing recognition of traditional Chinese medicine (TCM) by international medical authorities.

2024-06-17
Chase Sun Explore Potential Collaboration in Health Food Innovation

Chase Sun Pharma's Vice President Ms. Li Chunxu and Dr. Jackie Wang visited Monash University's Food Innovation Centre to discuss potential collaborations on health foods and functional products.

2024-05-15